Sleeve Plus™
Enhanced Metabolic Power.
Primary sleeve with advanced metabolic rerouting for superior, lasting weight loss and diabetes control.
What is Sleeve Plus™?
Sleeve Plus™ enhances standard sleeve gastrectomy with metabolic rerouting via an advanced duodeno-ileal anastomosis — designed for better long-term weight loss and diabetes control than sleeve alone.
Who it's for: Patients with primary obesity and metabolic concerns seeking durable, science-backed weight loss.
- Powerful restriction + enhanced metabolic rerouting
- Superior long-term outcomes vs standard sleeve
- Minimally invasive with reduced complication risk
- Synergistic with MyProgressMD pre/post-op protocols
A clear, precise pathway.
- 01
Restrictive sleeve creation
Precision laparoscopic sleeve gastrectomy reduces gastric volume.
- 02
Enhanced anastomosis
An advanced or magnetic-compression duodeno-ileal connection adds metabolic rerouting.
- 03
Natural healing & metabolic optimization
The body's gut hormones reset for sustained appetite, glucose, and lipid control.
Ready for Enhanced Metabolic Power?
Speak with our international care team today — same-week availability.
The science behind Sleeve Plus™.
Amplify your results with science-backed protocols.
Pair Sleeve Plus™ with personalized pre- and post-op bundles from MyProgressMD — engineered to support healing, nutrition, and long-term metabolic outcomes.
Shop Supplement BundlesCurrent Evidence Status
A transparent snapshot of the regulatory, clinical, and research evidence currently available for this procedure. Published evidence continues to evolve; long-term studies remain ongoing.
- FDA Regulatory Status— De Novo + 510(k) clearances Available
- Human Studies Published
- Peer-Reviewed Publications Published
- Long-Term Data (>5 years)— Follow-up ongoing Limited
- Ongoing Clinical Trials— Chile and Italy registries Active
Scientific References
Selected primary sources informing this page. External links open in a new tab; we do not control or endorse third-party content.
- FDAU.S. FDA — De Novo Classification DEN240013: MagDI System (Magnetic Duodeno-Ileostomy), De Novo marketing authorization granted July 2, 2024.
- FDAU.S. FDA — 510(k) Premarket Notification K242086: MagDI System (second generation), clearance granted October 24, 2024.
- FDAU.S. FDA — 510(k) Premarket Notification K243359: MagDI System 50 mm magnet, clearance granted in 2025.
- Obesity SurgeryGagner M, et al. First-in-human experience of magnetic duodeno-ileostomy for the treatment of obesity and metabolic disease. Obesity Surgery.
- Surgical EndoscopyMulti-center early outcomes of sleeve gastrectomy combined with magnetic duodeno-ileostomy (Sleeve Plus MagDI). Surgical Endoscopy.
- ASMBSAmerican Society for Metabolic and Bariatric Surgery (ASMBS) and IFSO 2022 indications for metabolic and bariatric surgery.
- NIDDKNational Institute of Diabetes and Digestive and Kidney Diseases — Bariatric Surgery for Severe Obesity.
Frequently asked questions
Your next step starts here.
Our international care team typically responds within one business day. WhatsApp available 24/7 for urgent inquiries.
Choose Enhanced Metabolic Power. Start today.
Limited slots for international patients. Same-week availability from San Diego.